Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30 participants
OBSERVATIONAL
2004-01-31
2006-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Meningioma and Embolism Thrombosis Risk & Investigation of Coagulation
NCT06709833
Platelets Activation in Brain Neoplasms
NCT05049148
Study of Tissue Samples From Patients With Glioma or Other Brain Tumors
NCT00967200
Biomarkers for Prognosis of Glioblastoma (GBM)
NCT01493219
Prospective Cohort of Patients With Newly Diagnosed Glioblastoma: Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features.
NCT03526822
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* adult patients
* newly diagnosed, biopsy-confirmed grade III/IV malignant gliomas
* undergone craniotomy or stereotactic biopsy \> 2 days and \< 4 weeks before
Exclusion Criteria
* are receiving experimental antiangiogenic therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ontario Cancer Research Network
NETWORK
Ontario Clinical Oncology Group (OCOG)
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Agnes Lee, MD
Role: STUDY_CHAIR
Hamilton Health Sciences and McMaster University
William Geerts, MD
Role: PRINCIPAL_INVESTIGATOR
Sunnybrook Health Sciences Centre
Mark Levine, MD
Role: PRINCIPAL_INVESTIGATOR
Ontario Clinical Oncology Group (OCOG)
James Perry, MD
Role: PRINCIPAL_INVESTIGATOR
Toronto Sunnybrook Regional Cancer Centre
Janusz Rak
Role: PRINCIPAL_INVESTIGATOR
Hamilton Health Sciences and McMaster University
Jeffrey Weitz, MD
Role: PRINCIPAL_INVESTIGATOR
Hamilton Health Sciences and McMaster University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Henry Ford Hospital
Detroit, Michigan, United States
Huntsman Cancer Institute
Salt Lake City, Utah, United States
Cross Cancer Institute
Edmonton, Alberta, Canada
CancerCare Manitoba
Winnipeg, Manitoba, Canada
Toronto-Sunnybrook Regional Cancer Centre
Toronto, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OCOG-2003-TFsubstudy
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.